Spontaneous subarachnoid haemorrage
Conditions
Interventions
Group 1: ARGIPRESSIN GROUP: This cohort consists of patients who received argipressin for induced arterial hypertension as part of their routine care for cerebral vasospasm, managed independently of t
Sponsors
University Hospital of Nantes (CHU de Nantes)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Adult patients (aged =18 years); - AND who received iHTN for cerebral vasospasm following non-traumatic SAH; - AND having received either argipressin for this iAH (argipressin group, for the primary objective) or norepinephrine > 1.5 µg/kg/min for at least 6 consecutive hours without argipressin (control group, for secondary objectives). - AND who were admitted to the general Intensive Care Unit (ICU) or the Intermediate Care Unit at Laennec Hospital during this iHTN, between September 2018 (implementation of electronic medical records) and 24th November 2025 (date of approval of the study by the Ethics Committee)
Exclusion criteria
Exclusion criteria: - Minors or protected adults (individuals under legal guardianship); - Pregnant or breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Exclusively within the argipressin group, to compare—before and 6 hours after the addition of argipressin to noradrenaline—the proportion of patients in whom the prescribed arterial pressure target was achieved as part of induced arterial hypertension (iHTN). Primary Outcome Measure: For the primary objective, each patient in the argipressin group will serve as their own control. A statistically significant difference (p < 0.05) will be sought to determine whether argipressin contributed to reaching the iHTN target | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Exclusively within the argipressin group: To apply the primary objective to other time points: comparing, before and after (H1, H2, H12, H24) the addition of argipressin to noradrenaline, the proportion of patients in whom the prescribed arterial pressure target was achieved as part of iHTN. 2. Exclusively within the argipressin group: To compare arterial pressure (mean, systolic, diastolic) before and after the addition of argipressin to noradrenaline (at H1, H2, H6, H12, and H24). 3. Exclusively within the argipressin group: To compare noradrenaline dosage before and after the addition of argipressin (at H1, H2, H6, H12, and H24). 4. Exclusively within the argipressin group: To compare heart rate before and after the addition of argipressin (at H1, H2, H6, H12, and H24). 5. Exclusively within the argipressin group: To compare nimodipine dosage before and after the addition of argipressin (at H1, H2, H6, H12, and H24). 6. Exclusively within the argipressin group: To compare milrinone dosage before and after the addition of argipressin (at H1, H2, H6, H12, and H24). 7. Exclusively within the argipressin group: To compare the proportion of patients in whom the dosage of nimodipine and/or milrinone could be increased following the addition of argipressin (at H1, H2, H6, H12, and H24). 8. Exclusively within the argipressin group: To compare intracranial pressure (where measurements were available) before and after the addition of argipressin (at H1, H2, H6, H12, and H24). 9. Exclusively within the argipressin group: To compare mean blood flow velocity in the middle cerebral arteries via transcranial Doppler (where measurements were available) before and after the addition of argipressin (at H1, H2, H6, H12, and H24). 10. Between the two groups: To compare the severity of angiographic vasospasm (last imaging prior to H0). A further comparison will examine the evolution of vasospasm between the last imaging prior to H0 and the first imaging following H0. 11. | — |
Countries
France
Contacts
Public ContactKarim Lakhal
University Hospital of Nantes (CHU de Nantes), France
Outcome results
None listed